Alan Zanardi, Ilaria Nardini, Sara Raia, Antonio Conti, Barbara Ferrini, Patrizia D'Adamo, Enrica Gilberti, Giuseppe DePalma, Sara Belloli, Cristina Monterisi, Angela Coliva, Paolo Rainone, Rosa Maria Moresco, Filippo Mori, Giada Zurlo, Carla Scali, Letizia Natali, Annalisa Pancanti, Pierangelo Giovacchini, Giulio Magherini, Greta Tovani, Laura Salvini, Vittoria Cicaloni, Cristina Tinti, Laura Tinti, Daniele Lana, Giada Magni, Maria Grazia Giovannini, Alessandro Gringeri, Andrea Caricasole, Massimo Alessio
Plasma-derived therapeutic proteins are produced through an industrial fractionation process where proteins are purified from individual intermediates, some of which remain unused and are discarded. Relatively few plasma-derived proteins are exploited clinically, with most of available plasma being directed towards the manufacture of immunoglobulin and albumin. Although the plasma proteome provides opportunities to develop novel protein replacement therapies, particularly for rare diseases, the high cost of plasma together with small patient populations impact negatively on the development of plasma-derived orphan drugs...
January 30, 2024: Communications Biology